Glucagon-like peptide-1 (GLP-1), an incretin hormone, is known to lower glucose levels, suppress glucagon secretion, and slow gastric emptying. These properties make GLP-1 an ideal target in treating type 2 diabetes mellitus (T2DM). There are many FDA-approved GLP-1 agonists on the market today, several of which have demonstrated benefit beyond improving glycemic control. Given the beneficial effects of GLP-1 agonists in patients with T2DM, new drugs are in development that combine the mechanism of action of GLP-1 receptor agonism with novel mechanisms and with drugs that promote GLP-1 secretion. These agents are designed to improve glycemic control and target greater body weight reduction. This article discusses new GLP-1 drugs in the pipeline for the treatment of T2DM.
National CDC. Diabetes Statistics Report 2020. Estimates of diabetes and its burden in the United States. Atlanta, GA: Centers for Disease Control and Prevention; 2020.
American Diabetes Association. Standards of medical care in diabetes - 2021. Diabetes Care. 2021;44(suppl 1):S15-S232.
4.
HinnenD. Glucagon-like peptide 1 receptor agonists for type 2 diabetes. Diabetes Spectr. 2017;30(3):202-210.
5.
Trulicity [package Insert]. Indianapolis, IN: Eli Lilly and Company; 2020.
6.
Byetta [package Insert]. Wilmington, DE: AstraZenica Pharmaceuticals LP; 2020.
7.
Bydureon [package Insert]. Wilmington, DE: AstraZenica Pharmaceuticals LP; 2020.
8.
Victoza [package Insert]. Bagsvaerd, Denmark: Novo Nordisk A/S; 2020.
9.
Ozempic [package Insert]. Bagsvaerd, Denmark: Novo Nordisk A/S; 2019.
10.
Rybelsus [package Insert]. Bagsvaerd, Denmark: Novo Nordisk A/S; 2020.
11.
Adlyxin [package Insert]. Bridgewater, NJ: Sanofi-Aventis US LLS; 2019.
12.
CoskunTSloopKWLoghinC, et al.LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018;18:3-14. DOI: 10.1016/j.molmet.2018.09.009
13.
PortronAJadidiSSarkarNDiMarchiRSchmittC. Pharmacodynamics, pharmacokinetics, safety and tolerability of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist RG7697 after single subcutaneous administration in healthy subjects. Diabetes Obes Metabol. 2017;19(10):1446-1453.
14.
TillnerJPoschMGWagnerF, et al.A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: results of randomized, placebo-controlled first-in-human and first-in-patient trials, Diabetes Obes Metabol. 2019;21(1):120-128.
15.
AmberyPDKlammtSPoschMG, et al.MEDI0382, a GLP-1/glucagon receptor dual agonist, meets safety and tolerability endpoints in a single-dose, healthy-subject, randomized, Phase 1 study. Br J Clin Pharmacol. 2018;84(10):2325-2335.
16.
YamadaYTerauchiYWatadaH, et al.Efficacy and safety of GPR119 agonist DS-8500a in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study. Adv Ther. 2018;35(3):367-381.
17.
KatzLBGambaleJJRothenbergPL, et al.Effects of JNJ-38431055, a novel GPR119 receptor agonist, in randomized, double-blind, placebo-controlled studies in subjects with type 2 diabetes. Diabetes Obes Metabol. 2012;14(8):709-716.
18.
RosenstockJSorliCHTrautmannME, et al.Once-weekly efpeglenatide dose-range effects on glycemic control and body weight in patients with type 2 diabetes on metformin or drug naive, referenced to liraglutide. Diabetes Care. 2019;42(9):1733-1741.
19.
FriasJPNauckMAVanJ, et al.Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet. 2018;392(10160):2180-2193.
20.
SchmittCPortronAJadidiSSarkarNDiMarchiR. Pharmacodynamics, pharmacokinetics and safety of multiple ascending doses of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist RG7697 in people with type 2 diabetes mellitus. Diabetes Obes Metabol. 2017;19(10):1436-1445.
21.
FriasJPBastyrEJVignatiL, et al.The sustained effects of a dual GIP/GLP-1 receptor agonist, NNC0090-2746, in patients with type 2 diabetes. Cell Metabol. 2017;26(2):343-352.
22.
AmberyPParkerVEStumvollM, et al.Articles MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study. Lancet. 2018. 391(10140):2607-2618.
23.
TerauchiYYamadaYWatadaH, et al.Efficacy and safety of the g protein-coupled receptor 119 agonist DS-8500a in Japanese type 2 diabetes mellitus patients with inadequate glycemic control on sitagliptin: a phase 2 randomized placebo-controlled study. J Diabetes Investig. 2018;9(6):1333-1341.
24.
PratleyREKangJTrautmannME, et al.Body weight management and safety with efpeglenatide in adults without diabetes: a phase II randomized study. Diabetes Obes Metabol. 2019;21(11):2429-2439.
25.
YangG-RZhaoX-LJinFShiL-HYangJ-K. Pharmacokinetics and pharmacodynamics of a polyethylene glycol (PEG)-conjugated GLP-receptor agonist once weekly in Chinese patients with type 2 diabetes. J Clin Pharmacol. 2015;55(2):152-158.
26.
ChenXLvXYangG, et al.Polyethylene glycol loxenatide injections added to metformin effectively improve glycemic control and exhibit favorable safety in type 2 diabetic patients. J Diabetes. 2017;9(2):158-167.
27.
ZangYNZhangMJWangYT, et al.Population pharmacokinetics of lyophilized recombinant glucagon-like peptide-1 receptor agonist (recombinant exendin-4, rE-4) in Chinese patients with type 2 diabetes mellitus. Int J Clin Pharm Ther. 2017;55(8):650-658.
28.
WangYXuBZhuL, et al.Pharmacokinetics and preliminary pharmacodynamics of single- and multiple-dose lyophilized recombinant glucagon-like peptide-1 receptor agonist (rE-4) in Chinese patients with type 2 diabetes mellitus. Clin Drug Invest. 2017;37(12):1107-1115.
29.
TorekovSSKipnesMSHarleyREHolstJJEhlersMR. Dose response of subcutaneous GLP-1 infusion in patients with type 2 diabetes. Diabetes Obes Metabol. 2011;13(7):639-643.
30.
TorekovSSHolstJJEhlersMR. Dose response of continuous subcutaneous infusion of recombinant glucagon-like peptide-1 in combination with metformin and sulphonylurea over 12 weeks in patients with type 2 diabetes mellitus. Diabetes Obes Metabol. 2014;16(5):451-456.
